Selskabets formål er at udvikle ideer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller ideer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 140.8 mio. | -38.8 mio. | 78.1 mio. | -935.6 mio. | 0 | |
CVR: 32323537
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
The financial health of Ascendis Pharma Endocrinology Division A/S shows significant concerns, particularly with ongoing losses and negative equity. In 2025, the company reported revenue of 140.8 million DKK but incurred a loss of 38.8 million DKK, indicating a slight improvement in profitability compared to the previous year's loss of 121.1 million DKK on revenue of 122.9 million DKK. However, the equity position remains precarious, with a negative equity of -935.7 million DKK, reflecting a deteriorating financial trajectory over the past few years. The company operates in the pharmaceutical manufacturing industry, where it faces challenges in achieving sustainable profitability and managing its debt levels effectively.
AI-generated summary
Companies in the same industry and area
CVR 29918791
CVR 32323502
CVR 32323596
CVR 32323677
CVR 41034076
companydata.dk